Clinical data
Routes of
ATC code none
Legal status
Legal status
  • Never marketed
Synonyms 1-(4-methyl-3-oxo-4-aza-5-alpha-androstane-17-beta-carbonyl)-1,3- diisopropylurea
CAS Number 137099-09-3
PubChem (CID) 65986
ChemSpider 59380
Chemical and physical data
Formula C27H45N3O3
Molar mass 459.66 g/mol
3D model (Jmol) Interactive image

Turosteride (FCE-26,073) is a selective inhibitor of the enzyme 5α-reductase which was under investigation by GlaxoSmithKline for the treatment of benign prostatic hyperplasia (BPH), but was never marketed.[1][2][3] Similarly to finasteride, turosteride is selective for the type II isoform of 5α-redcutase, with about 15-fold selectivity for it over type I isoform of the enzyme.[4][5] In animal studies it has been shown to inhibit prostate size and retard tumor growth.[2][3][6][7] It may also be useful for the treatment of acne and hair loss.[8][9][10]

See also


  1. David J. Triggle (1996). Dictionary of Pharmacological Agents. Boca Raton: Chapman & Hall/CRC. ISBN 0-412-46630-9.
  2. 1 2 di Salle E, Giudici D, Briatico G, Ornati G, Panzeri A (November 1993). "Hormonal effects of turosteride, a 5 alpha-reductase inhibitor, in the rat". The Journal of Steroid Biochemistry and Molecular Biology. 46 (5): 549–55. doi:10.1016/0960-0760(93)90181-U. PMID 8240976.
  3. 1 2 Di Salle E, Briatico G, Giudici D, Ornati G, Panzeri A (February 1994). "Endocrine properties of the testosterone 5 alpha-reductase inhibitor turosteride (FCE 26073)". The Journal of Steroid Biochemistry and Molecular Biology. 48 (2-3): 241–8. doi:10.1016/0960-0760(94)90151-1. PMID 8142301.
  4. Iehlé C, Délos S, Guirou O, Tate R, Raynaud JP, Martin PM (September 1995). "Human prostatic steroid 5 alpha-reductase isoforms--a comparative study of selective inhibitors". The Journal of Steroid Biochemistry and Molecular Biology. 54 (5-6): 273–9. doi:10.1016/0960-0760(95)00134-L. PMID 7577710.
  5. Seiffert K, Seltmann H, Fritsch M, Zouboulis CC (February 2007). "Inhibition of 5alpha-reductase activity in SZ95 sebocytes and HaCaT keratinocytes in vitro". Hormone and Metabolic Research = Hormon- Und Stoffwechselforschung = Hormones Et Métabolisme. 39 (2): 141–8. doi:10.1055/s-2007-961814. PMID 17326010.
  6. Zaccheo T, Giudici D, di Salle E (February 1997). "Effect of turosteride, a 5 alpha-reductase inhibitor, on the Dunning R3327 rat prostatic carcinoma". The Prostate. 30 (2): 85–91. doi:10.1002/(SICI)1097-0045(19970201)30:2<85::AID-PROS3>3.0.CO;2-J. PMID 9051146.
  7. Zaccheo T, Giudici D, di Salle E (June 1998). "Effect of early treatment of prostate cancer with the 5alpha-reductase inhibitor turosteride in Dunning R3327 prostatic carcinoma in rats". The Prostate. 35 (4): 237–42. doi:10.1002/(SICI)1097-0045(19980601)35:4<237::AID-PROS1>3.0.CO;2-D. PMID 9609545.
  8. Rawlings, Anthony V.; Webster, Guy F. (2007). Acne and its therapy. New York: Informa Healthcare USA. ISBN 0-8247-2971-4.
  9. "Hairloss Treatment: Turosteride".
  10. "Hair Loss Drugs - Turosteride - competitive and specific inhibitor of Type II 5a-reductase. - Database of Drugs for Hair Loss".
This article is issued from Wikipedia - version of the 11/5/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.